Category: Publications

Search News
Categories
Archives
Immune therapy reduces risk of recurrence in aggressive breast cancer

27th February 2020

An immune therapy for the most aggressive form of breast cancer can substantially reduce the risk of the disease returning, according to a clinical trial led by Professor Peter Schmid of Barts Cancer Institute, Queen Mary University of London.

Read more

Foot-and-mouth-disease virus could help target pancreatic cancer

12th February 2020

Researchers at Barts Cancer Institute, Queen Mary University of London, have identified a peptide, or protein fragment, taken from the foot-and-mouth-disease virus that targets another protein, called avβ6 (alpha-v-beta-6). This protein is found at high levels on the surface of the majority of pancreatic cancer cells.

Read more

Mouse models of ovarian cancer

27th January 2020

Research led by the Barts Cancer Institute, Queen Mary University of London, has revealed that mouse models of the most common and deadly form of ovarian cancer, high-grade serous ovarian cancer, can effectively replicate the disease in humans. These models provide useful pre-clinical tools that may help to determine which patients are likely to respond to particular treatments.

Read more

Protein network rewiring in cancer

20th January 2020

Research published in Nature Biotechnology has identified new ways to analyse the complexity of the internal workings of normal cells and cancer cells. The study highlights how genetic changes rewire the biochemistry of cancer cells and may aid in identifying new drug targets specific for a patient’s disease.

Read more

Tackling resistance in skin cancer

13th January 2020

Researchers have found that melanoma cells fight anti-cancer drugs by changing their internal skeleton (cytoskeleton) – opening up a new therapeutic route for combating skin and other cancers that develop resistance to treatment.

Read more

IBIS-II – new results from international breast cancer study

12th December 2019

The Queen Mary University of London professor leading an international breast cancer study says anastrozole – rather than tamoxifen – should be the preventive drug-of-choice for post-menopausal women at increased risk of developing the disease.

Read more

Search News
Categories
Archives
Upcoming Events
  1. The London Pancreas Workshop 2020

    May 1 @ 9:30 am - 4:30 pm
  2. 2020 Circulating Cancer Biomarker Symposium

    May 4 @ 9:00 am - 5:30 pm
© 2013 ~ 2020 Cancer Research UK Barts Centre